I agree that this site is using cookies. You can find further informations here.
X
Pignata, S.
939  results:
Search for persons X
?
1

47MO The risk index of early relapse defined by MiROvaR, a ..:

Bagnoli, M. ; De Cecco, L. ; Califano, D....
ESMO Open.  9 (2024)  - p. 103554 , 2024
Link: https://doi.org/10.1016/..
 
?
2

29P fT3/fT4 ratio, systemic inflammation and skeletal muscl..:

Tuninetti, V. ; Virano, E. ; Calvo, A....
ESMO Open.  9 (2024)  - p. 103529 , 2024
Link: https://doi.org/10.1016/..
 
?
3

39MO Phase III ENGOT-En9/LEAP-001 study: Lenvatinib + pembr..:

Pignata, S. ; Marth, C. ; Moore, R.G....
ESMO Open.  9 (2024)  - p. 103539 , 2024
Link: https://doi.org/10.1016/..
 
?
4

66P PARPi and myeloid neoplasia: The Italian MITO-MaNGO exp..:

Turinetto, M. ; Marchetti, C. ; Boccia, S.M....
ESMO Open.  9 (2024)  - p. 103573 , 2024
Link: https://doi.org/10.1016/..
 
?
5

45MO Management of stage I ovarian Sertoli-Leydig cell tumo..:

Bergamini, A. ; Sabetta, G. ; Fruscio, R....
ESMO Open.  9 (2024)  - p. 103552 , 2024
Link: https://doi.org/10.1016/..
 
?
6

MITO END-3: efficacy of avelumab immunotherapy according to..:

Pignata, S. ; Califano, D. ; Lorusso, D....
Annals of Oncology.  35 (2024)  7 - p. 667-676 , 2024
Link: https://doi.org/10.1016/..
 
?
7

28P Real-life efficacy and safety of cemiplimab in advanced..:

Tuninetti, V. ; Virano, E. ; Salutari, V....
ESMO Open.  9 (2024)  - p. 103528 , 2024
Link: https://doi.org/10.1016/..
 
?
8

Under-reporting of subjective symptoms and its prognostic v..:

Arenare, L. ; Di Liello, R. ; De Placido, P....
ESMO Open.  9 (2024)  3 - p. 102941 , 2024
Link: https://doi.org/10.1016/..
 
?
9

Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carb..:

Vergote, I. ; Van Nieuwenhuysen, E. ; Casado, A....
Gynecologic Oncology.  174 (2023)  - p. 80-88 , 2023
Link: https://doi.org/10.1016/..
 
?
10

73TiP Niraparib maintenance in first-line ovarian cancer: M..:

Di Napoli, M. ; Pignata, S.
ESMO Open.  8 (2023)  1 - p. 100853 , 2023
Link: https://doi.org/10.1016/..
 
?
11

45P MITO39: Effiacy and tolerability of PLD-trabectedin in ..:

Turinetto, M. ; Pignata, S. ; Pisano, C....
ESMO Open.  8 (2023)  1 - p. 100825 , 2023
Link: https://doi.org/10.1016/..
 
?
12

P080 Using your Mobile/Tablet Device at Bedtime for Work: I..:

Lushington, K ; Markobotsaris, M ; Dollard, M...
Sleep Advances.  4 (2023)  Supplement_1 - p. A65-A66 , 2023
Link: https://doi.org/10.1093/..
 
?
13

51P Efficacy of PARP inhibitors in patients with advanced h..:

Buonaiuto, R. ; Neola, G. ; Parola, S....
ESMO Open.  8 (2023)  1 - p. 100831 , 2023
Link: https://doi.org/10.1016/..
 
?
14

39MO Clinical evaluation of a low-coverage whole-genome tes..:

Boidot, R. ; Blum, M.G.B. ; Wissler, M-P....
ESMO Open.  8 (2023)  1 - p. 100819 , 2023
Link: https://doi.org/10.1016/..
 
?
15

23P Pre-treatment inflammatory indexes predict the clinical..:

Farolfi, A. ; Scarpi, E. ; Loizzi, V....
ESMO Open.  8 (2023)  1 - p. 100794 , 2023
Link: https://doi.org/10.1016/..
 
1-15